We report that GzB-IL18 demonstrates biological activity that is strictly dependent on T cell activation, thereby potentiating the anti-tumor activity of CAR-engineered αβ or γδ T cells in an antigen-dependent manner. The gene discussed is IL18; the disease is neoplasm.